These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21410862)

  • 1. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
    Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
    HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
    J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
    Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC
    Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients.
    Bartolini B; Giombini E; Zaccaro P; Selleri M; Rozera G; Abbate I; Comandini UV; Ippolito G; Solmone M; Capobianchi MR
    Virus Res; 2013 Nov; 177(2):205-8. PubMed ID: 23954579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients.
    Cao Y; Bao Y; Xia W; Wu H; Wei F; Zhang Y; Zhang R; Xu X
    Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):597-604. PubMed ID: 27016893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
    Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
    Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.
    Bagaglio S; Messina E; Hasson H; Merli M; Andolina A; Lazzarin A; Uberti-Foppa C; Morsica G
    New Microbiol; 2017 Jan; 40(1):53-55. PubMed ID: 28072886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus.
    Winters MA; Welles SL; Holodniy M
    J Virol; 2006 Apr; 80(8):4196-9. PubMed ID: 16571838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.
    Aissa Larousse J; Trimoulet P; Recordon-Pinson P; Papuchon J; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
    J Med Virol; 2014 Aug; 86(8):1350-9. PubMed ID: 24760718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
    Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
    J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
    Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
    Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients.
    Peres-da-Silva A; de Almeida AJ; Lampe E
    Arch Virol; 2010 May; 155(5):807-11. PubMed ID: 20405151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients.
    Winters MA; Chary A; Eison R; Asmuth D; Holodniy M
    J Med Virol; 2010 May; 82(5):791-8. PubMed ID: 20336744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
    de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
    J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
    Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
    Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
    J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.